Continued Antiarrhythmic Medication (Class) and Dose Uses in VA/SCA Target Electrophysiological Effects Pharmacological Characteristics Common Adverse Effects (Continued) CLINICAL STATEMENTS AND GUIDELINES ICD without a history of documented VT/VF and with one of the following conditions: BUN 26 mg/dL, QRS >120 msec, atrial fibrillation, or NSVT or >500 VPBs on 24-hour Holter recording; 2) having a primary preven- tion ICD with a history of documented VT/VF appropri- ately treated with ICD therapy or untreated NSVT; or 3) having a secondary prevention ICD after documented VT/VF or cardiac arrest. Ranolazine did not significantly reduce the primary endpoint of VT/VF requiring appro- priate ICD therapy or death. In a prespecified secondary analysis, ranolazine was associated with a significant reduction in VT events treated with anti-tachycardia 5.1.2. 